Biomarkers of Neurodegenerative Disorders.

By Rawan Tarawneh

ISBN: 9783031808487
Published: July 2025
Publisher: Springer Cham
Pages: 637, Hardcover

Description:

Current Progress and Future Directions

This book presents state-of-the-art knowledge regarding fluid and imaging biomarkers of neurodegenerative disorders, including Alzheimer disease and related dementias (ADRD). A cadre of top experts discuss the diagnostic and prognostic value of established and emerging biomarkers in ADRD, their ability to track disease progression or predict cognitive outcomes, and their potential as novel therapeutic targets.

Biomarkers are discussed in the context of specific disease mechanisms — amyloid, tau, and synuclein pathologies, endothelial, vascular, neuronal and synaptic injury, and glial reactivity — across a wide spectrum of neurodegenerative disorders. Multi-omics approaches including proteomics, genomics, and transcriptomics are covered, and the authors highlight the need to integrate biomarkers into ADRD drug development to accelerate discovery and approval.

Table of Contents

Fluid and Imaging Markers of Amyloid, Tau and Synuclein Pathology. Fluid and Imaging Markers of Synaptic, Axonal and Neuronal Injury. Markers of Glial Reactivity and Vascular Disease. Fluid Markers of Alzheimer Disease. Markers of Frontotemporal Lobar Degeneration, Lewy Body Dementias and Huntington's Disease. Proteomics, Genomics and Transcriptomics for Biomarker Discovery. Biomarkers in Clinical Trials of Alzheimer Disease. Sex Differences in Alzheimer Disease Biomarkers.

Keywords

biomarkers, neurodegenerative disorders, Parkinson's disease, dementia, Alzheimer's, neuropharmacology, frontotemporal dementia, Lewy body dementia

Target Audience

Neurologists, neuroscientists, clinical researchers, graduate students, pharmaceutical professionals

Genre

Medical Science, Neuroscience, Academic Reference, Clinical Research, Biotechnology

Q&A

Q: Where can I buy Biomarkers of Neurodegenerative Disorders?
A: You can order this book directly from CLNZ Books at clnzbooks.com, with worldwide shipping and secure payment by credit card or PayPal.

Q: What disease mechanisms does the book address?
A: Amyloid, tau and synuclein pathologies, vascular and synaptic injury, and glial reactivity across Alzheimer's and related dementias.

Q: Does it cover multi-omics approaches?
A: Yes — proteomics, genomics and transcriptomics for biomarker and drug target discovery in Alzheimer disease.

Q: Why does biomarker integration matter for drug development?
A: The authors argue it can accelerate ADRD drug discovery and approval by tracking disease progression and predicting outcomes.

Q: Who is this book for?
A: Neurologists, neuroscientists, clinical researchers, and pharmaceutical professionals.

How to Order

Learn more about how to order from CLNZ Books, including worldwide shipping and payment options.